Drug Resistance, Bacterial
"Drug Resistance, Bacterial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
| Descriptor ID |
D024881
|
| MeSH Number(s) |
G06.099.225 G06.225.347 G07.690.773.984.269.347
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Bacterial".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Bacterial".
This graph shows the total number of publications written about "Drug Resistance, Bacterial" by people in this website by year, and whether "Drug Resistance, Bacterial" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 7 | 7 |
| 2004 | 1 | 5 | 6 |
| 2005 | 7 | 6 | 13 |
| 2006 | 6 | 7 | 13 |
| 2007 | 4 | 5 | 9 |
| 2008 | 4 | 9 | 13 |
| 2009 | 3 | 5 | 8 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 4 | 9 |
| 2012 | 6 | 3 | 9 |
| 2013 | 8 | 8 | 16 |
| 2014 | 5 | 8 | 13 |
| 2015 | 5 | 12 | 17 |
| 2016 | 6 | 9 | 15 |
| 2017 | 4 | 10 | 14 |
| 2018 | 5 | 8 | 13 |
| 2019 | 5 | 5 | 10 |
| 2020 | 4 | 7 | 11 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 9 | 10 |
| 2023 | 1 | 7 | 8 |
| 2024 | 6 | 6 | 12 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Bacterial" by people in Profiles.
-
Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023. Emerg Infect Dis. 2025 Mar; 31(3):615-617.
-
Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis. BMC Med. 2024 Dec 23; 22(1):598.
-
Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
-
Overcoming the effects of increasing antimicrobial resistance on Helicobacter pylori therapy. Expert Rev Gastroenterol Hepatol. 2024 Nov; 18(11):705-711.
-
Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites. Antimicrob Agents Chemother. 2024 Dec 05; 68(12):e0120624.
-
Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam. Helicobacter. 2024 Nov-Dec; 29(6):e13149.
-
A successful UN High-Level Meeting on antimicrobial resistance must build on the 2023 UN High-Level Meeting on tuberculosis. Lancet Glob Health. 2024 Aug; 12(8):e1225-e1226.
-
Synergistic effects of novel penicillin-binding protein 1A amino acid substitutions contribute to high-level amoxicillin resistance of Helicobacter pylori. mSphere. 2024 Aug 28; 9(8):e0008924.
-
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin. Antimicrob Agents Chemother. 2024 08 07; 68(8):e0012724.
-
Mutations Affecting Cellular Levels of Cobalamin (Vitamin B12) Confer Tolerance to Bactericidal Antibiotics in Burkholderia cenocepacia. J Microbiol Biotechnol. 2024 Aug 28; 34(8):1609-1616.